JP6092883B2 - 無効赤血球生成を処置するための方法および組成物 - Google Patents

無効赤血球生成を処置するための方法および組成物 Download PDF

Info

Publication number
JP6092883B2
JP6092883B2 JP2014537186A JP2014537186A JP6092883B2 JP 6092883 B2 JP6092883 B2 JP 6092883B2 JP 2014537186 A JP2014537186 A JP 2014537186A JP 2014537186 A JP2014537186 A JP 2014537186A JP 6092883 B2 JP6092883 B2 JP 6092883B2
Authority
JP
Japan
Prior art keywords
actriib
polypeptide
seq
gdf trap
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014537186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530253A5 (enExample
JP2014530253A (ja
Inventor
ジャスバー シーラー，
ジャスバー シーラー，
ロバート スコット ピアソール，
ロバート スコット ピアソール，
ラビンドラ クマール，
ラビンドラ クマール，
ナガ ベンカタ サイ ラジャセカール スラガニ，
ナガ ベンカタ サイ ラジャセカール スラガニ，
Original Assignee
アクセルロン ファーマ， インコーポレイテッド
アクセルロン ファーマ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクセルロン ファーマ， インコーポレイテッド, アクセルロン ファーマ， インコーポレイテッド filed Critical アクセルロン ファーマ， インコーポレイテッド
Publication of JP2014530253A publication Critical patent/JP2014530253A/ja
Publication of JP2014530253A5 publication Critical patent/JP2014530253A5/ja
Application granted granted Critical
Publication of JP6092883B2 publication Critical patent/JP6092883B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2014537186A 2011-10-17 2012-10-17 無効赤血球生成を処置するための方法および組成物 Active JP6092883B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161547932P 2011-10-17 2011-10-17
US61/547,932 2011-10-17
PCT/US2012/060650 WO2013059347A1 (en) 2011-10-17 2012-10-17 Methods and compositions for treating ineffective erythropoiesis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017022176A Division JP6383821B2 (ja) 2011-10-17 2017-02-09 無効赤血球生成を処置するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2014530253A JP2014530253A (ja) 2014-11-17
JP2014530253A5 JP2014530253A5 (enExample) 2015-12-10
JP6092883B2 true JP6092883B2 (ja) 2017-03-08

Family

ID=48141315

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014537186A Active JP6092883B2 (ja) 2011-10-17 2012-10-17 無効赤血球生成を処置するための方法および組成物
JP2017022176A Active JP6383821B2 (ja) 2011-10-17 2017-02-09 無効赤血球生成を処置するための方法および組成物
JP2018147507A Active JP6796626B2 (ja) 2011-10-17 2018-08-06 無効赤血球生成を処置するための方法および組成物
JP2020140889A Pending JP2020186277A (ja) 2011-10-17 2020-08-24 無効赤血球生成を処置するための方法および組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017022176A Active JP6383821B2 (ja) 2011-10-17 2017-02-09 無効赤血球生成を処置するための方法および組成物
JP2018147507A Active JP6796626B2 (ja) 2011-10-17 2018-08-06 無効赤血球生成を処置するための方法および組成物
JP2020140889A Pending JP2020186277A (ja) 2011-10-17 2020-08-24 無効赤血球生成を処置するための方法および組成物

Country Status (13)

Country Link
US (4) US20130243743A1 (enExample)
EP (3) EP3520805B1 (enExample)
JP (4) JP6092883B2 (enExample)
KR (4) KR102079482B1 (enExample)
CN (3) CN107837390A (enExample)
AU (4) AU2012326207B2 (enExample)
BR (3) BR122019023166B1 (enExample)
CA (1) CA2852683A1 (enExample)
DK (2) DK3520805T3 (enExample)
EA (2) EA202090053A3 (enExample)
ES (3) ES2869168T3 (enExample)
HK (2) HK1250341A1 (enExample)
WO (1) WO2013059347A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2561048T3 (es) 2004-07-23 2016-02-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
ME00380B (me) 2005-11-23 2011-10-10 Acceleron Pharma Inc Amtagonisti aktivin-actriia i primjene za stimulaciju rasta kosti
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US9526759B2 (en) 2007-02-01 2016-12-27 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
KR101672156B1 (ko) 2007-02-09 2016-11-02 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
CN107412734A (zh) 2007-09-18 2017-12-01 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
LT3750552T (lt) 2008-08-14 2023-06-26 Acceleron Pharma Inc. Gdf gaudyklės
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
MX385318B (es) 2009-06-08 2025-03-18 Acceleron Pharma Inc Metodos para aumentar adipocitos termogenicos.
JP2012529294A (ja) 2009-06-12 2012-11-22 アクセルロン ファーマ， インコーポレイテッド 切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質
ES2613523T3 (es) * 2009-09-09 2017-05-24 Acceleron Pharma, Inc. Antagonistas de ActRIIb y dosificación y usos de los mismos
EP2501400B1 (en) 2009-11-17 2017-11-01 Acceleron Pharma, Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
WO2012064771A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma, Inc. Actriia binding agents and uses thereof
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
RU2018145985A (ru) 2012-11-02 2019-02-18 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
KR102520970B1 (ko) * 2014-03-21 2023-04-12 악셀레론 파마 인코포레이티드 액티빈 b 및/또는 gdf11을 억제함으로써 적혈 혈액 세포 수준을 증가시키고 비효율적인 적혈구 생성을 치료하는 방법
MX388380B (es) * 2014-04-18 2025-03-19 Acceleron Pharma Inc Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
DK3227675T3 (da) * 2014-12-03 2023-05-30 Celgene Corp Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom
DK3286206T3 (da) 2015-04-22 2021-05-03 Biogen Ma Inc Hidtil ukendte hybride actriib-ligand-trap-proteiner til behandling af muskelsvindsygdomme
WO2016183280A1 (en) * 2015-05-13 2016-11-17 Celgene Corporation Treatment of beta-thalassemia using actrii ligand traps
CN108350057A (zh) * 2015-05-20 2018-07-31 细胞基因公司 使用II型活化素受体配体阱的用于β-地中海贫血的体外细胞培养方法
EP3370754A4 (en) * 2015-11-04 2019-10-23 Acceleron Pharma Inc. METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE
CA3005975A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
EA201990226A1 (ru) 2016-07-27 2019-08-30 Акселерон Фарма Инк. Способы и композиции для лечения миелофиброза
JP7280182B2 (ja) 2016-10-05 2023-05-23 アクセルロン ファーマ インコーポレイテッド バリアントＡｃｔＲＩＩＢタンパク質およびその使用
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
WO2018089715A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
SMT202400437T1 (it) 2017-06-14 2024-11-15 Celgene Corp Metodi per trattare mielofibrosi associata a neoplasia mieloproliferativa e anemia
KR20250059538A (ko) 2017-11-09 2025-05-02 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
JP7510875B2 (ja) 2018-01-12 2024-07-04 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉｂ型受容体変異体および同変異体を含む医薬組成物
KR20250133994A (ko) 2018-05-09 2025-09-09 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
KR20230004515A (ko) 2020-03-20 2023-01-06 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 ii 키메라 및 이의 사용 방법
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
CA3177830A1 (en) 2020-05-13 2021-11-18 Maria BECONI Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1265208A (en) 1915-09-07 1918-05-07 Edward C Kahn Liquid-fuel burner.
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
ATE352638T1 (de) 1995-04-11 2007-02-15 Gen Hospital Corp REVERSE ßTWO-HYBRIDß-SYSTEME
US5807839A (en) * 1997-04-15 1998-09-15 Advanced Viral Research Corp. Method for stimulating red blood cell production
EP1147413B1 (en) 1999-01-21 2006-04-05 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
US7842691B2 (en) * 2002-10-15 2010-11-30 Celgene Corporation Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide
ES2561048T3 (es) 2004-07-23 2016-02-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
LT3750552T (lt) * 2008-08-14 2023-06-26 Acceleron Pharma Inc. Gdf gaudyklės
US8216997B2 (en) * 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
CA2770822C (en) * 2009-08-13 2020-03-24 Acceleron Pharma Inc. Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels

Also Published As

Publication number Publication date
CA2852683A1 (en) 2013-04-25
ES2741477T3 (es) 2020-02-11
ES3010483T3 (en) 2025-04-03
EP2797620B1 (en) 2019-04-24
JP2018165287A (ja) 2018-10-25
EP3875104B1 (en) 2025-01-22
EA202090053A3 (ru) 2020-06-30
BR112014009528A2 (pt) 2017-05-09
US20130243743A1 (en) 2013-09-19
AU2018247262B2 (en) 2020-12-24
HK1203413A1 (en) 2015-10-30
KR20220075438A (ko) 2022-06-08
AU2017201580A1 (en) 2017-03-30
EA201490809A1 (ru) 2014-09-30
KR20140084211A (ko) 2014-07-04
US20170327800A1 (en) 2017-11-16
DK3875104T3 (da) 2025-02-03
BR122019023166B1 (pt) 2021-02-23
CN103987403A (zh) 2014-08-13
EA202090053A2 (ru) 2020-04-30
EP2797620A1 (en) 2014-11-05
EP3875104A1 (en) 2021-09-08
HK1250341A1 (zh) 2018-12-14
CN103987403B (zh) 2017-12-01
US20170137791A1 (en) 2017-05-18
EP2797620A4 (en) 2015-05-20
JP2014530253A (ja) 2014-11-17
AU2020286229A1 (en) 2021-01-07
BR112014009528B1 (pt) 2020-12-29
US20210207107A1 (en) 2021-07-08
EA034563B1 (ru) 2020-02-20
WO2013059347A1 (en) 2013-04-25
BR122019023174B1 (pt) 2021-02-23
JP2020186277A (ja) 2020-11-19
KR20200019261A (ko) 2020-02-21
JP2017101060A (ja) 2017-06-08
AU2012326207A1 (en) 2014-05-15
KR102079482B1 (ko) 2020-02-19
JP6383821B2 (ja) 2018-08-29
DK3520805T3 (da) 2021-04-19
HK1252940A1 (zh) 2019-06-06
KR20190105113A (ko) 2019-09-11
ES2869168T3 (es) 2021-10-25
AU2018247262A1 (en) 2018-11-01
CN107837390A (zh) 2018-03-27
AU2012326207B2 (en) 2016-12-15
BR112014009528A8 (pt) 2019-12-10
EP3520805B1 (en) 2021-03-10
EP3520805A1 (en) 2019-08-07
CN107693776A (zh) 2018-02-16
AU2017201580B2 (en) 2018-07-12
JP6796626B2 (ja) 2020-12-09

Similar Documents

Publication Publication Date Title
JP6383821B2 (ja) 無効赤血球生成を処置するための方法および組成物
JP7329573B2 (ja) 赤血球レベルを高めるためのｇｄｆトラップの使用
JP5909446B2 (ja) 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用
HK40011608A (en) Compositions for treating myelofibrosis
HK40011608B (en) Compositions for treating myelofibrosis
HK40041550A (en) Gdf traps
HK1203413B (en) Compositions for treating iron overload in thalassemia
HK1232466A1 (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
HK1232466B (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
HK1171970A (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
HK1171970B (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151016

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161102

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170209

R150 Certificate of patent or registration of utility model

Ref document number: 6092883

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250